Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 1999Journal of Antimicrobial Chemotherapy

In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMohammad Ashraf HossainTongji UniversitySMShigefumi MaesakiSaitama Medical UniversityKMKotaro MitsutakeSaitama Medical University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hossain et al. (1999) studied this question.

synapsesocial.com/papers/6a702f5835aa2c282ce17b58https://doi.org/10.1093/jac/44.6.827
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Detection of Cryptococcus neoformans gene in patients with pulmonary cryptococcosis1996 · 50 citations
  2. 2Resistant P45051A1 activity in azole antifungal tolerant <i>Cryptococcus neoformans</i> from AIDS patients1995 · 65 citations
  3. 3Emergence of azole drug resistance in <i>Candida</i> species from HIV-infected patients receivingprolonged fluconazole therapy for oral candidosis1995 · 256 citations
  4. 4Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp1997 · 56 citations
  5. 5In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts1997 · 83 citations